• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke
Circ Res. 2022 Apr 15;130(8):1167-1186. doi: 10.1161/CIRCRESAHA.121.319994. Epub 2022 Apr 14.ABSTRACTInflammation and immune mechanisms are crucially involved in the pathophysiology of the development, acute damage cascades, and chronic course after ischemic stroke. Atherosclerosis is an inflammatory disease, and, in addition to classical risk factors, maladaptive immune mechanisms lead to an increased risk of stroke. Accordingly, individuals with signs of inflammation or corresponding biomarkers have an increased risk of stroke. Anti-inflammatory drugs, such as IL (interleukin)-1β blockers, methotrexate, or colchicine, r...
Source: Atherosclerosis - April 14, 2022 Category: Cardiology Authors: Matthias Endres Maria A Moro Christian H Nolte Claudia Dames Marion S Buckwalter Andreas Meisel Source Type: research

Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes
AbstractHyperuricemia and gout have been linked to an increased risk for cardiovascular (CV) disease, stroke, hypertension, heart failure, and chronic kidney disease, possibly through a proinflammatory milieu. However, not all the drugs used in gout treatment improve CV outcomes; colchicine has shown improved CV outcomes in patients with recent myocardial infarction and stable coronary artery disease independent of lipid-lowering effects. There is resurging interest in colchicine following publication of the COLCOT, LoDoCo, LoDoCo2, LoDoCo-MI trials,  and COLCORONA trial which will shed light on its utility in COVID-19. ...
Source: American Journal of Cardiovascular Drugs - December 28, 2020 Category: Cardiology Source Type: research